# 1. Financial Performance ## A. Key Figures * **Total Revenue:** **₹879 Cr** (Q1 FY'26) (+26.8% YoY, +9.6% QoQ) · **₹872 Cr** consolidated ops (+26.6% YoY, +9.4% QoQ) * EBITDA: ₹200 Cr (Q1 FY'26) (+8.5% YoY, -1.4% QoQ) · ₹194 Cr pre-Ind AS (+9.8% YoY, -1.5% QoQ) * **PAT:** **₹85 Cr** (Q1 FY'26) vs. ₹95 Cr YoY and ₹106 Cr QoQ * **EPS:** **₹1.96** (Q1 FY'26) (-9.2% YoY) * **Net Debt:** **₹2,020 Cr** (as of 30 Jun 2025) ## B. Revenue Growth * **Regional Contribution:** Thane, Nashik, and Kollam hospitals each delivered **INR5–9 crores** in revenue, highlighting balanced regional performance. ## C. Profitability Trends * **Margin Compression:** EBITDA margin improved to **7%** despite sequential decline in absolute EBITDA, indicating relative cost resilience. * **New Unit Drag:** EBITDA pressure persists from new facilities, with **INR80 crores** in incremental costs; Bangalore unit expected to reach EBITDA breakeven by Q2 FY27. * **Profit Decline:** Bottom-line contraction reflects higher base in prior periods and ongoing investment phase costs, partially offset by operating scale. ## D. Balance Sheet * **Leverage Position:** Net debt remains stable post-expansion, consistent with capital-intensive growth trajectory. --- # 2. Occupancy & Volume Trends ## A. Key Figures * **IP Volume Growth:** **5%–6% YoY** Telangana cluster · **Similar growth** expected in Andhra cluster * **Occupancy:** **50%–55%** current at Thane (July) · **65%–70%** achievable in Telangana cluster · **55%–60%** cluster-wide in Andhra & Telangana * **Revenue:** **₹9 Cr** Thane (July) · **₹7 Cr** Nashik (last month) * **EBITDA Loss:** **₹21 Cr** total (Thane: ₹11 Cr, Nashik: ₹7 Cr, Kannur: ₹3.5 Cr) * **Margin Expansion:** **40%** of incremental revenue contributes to margin at Sunshine and Nagpur * **Steady-State EBITDA Margin:** **20%–25%** per matured hospital cluster ## B. IP Volume Growth * **Mature Market Growth:** Telangana to deliver mid-single-digit IP volume growth, with acceleration expected next year following **Kondapur and Gachibowli expansions**. * **Andhra Parity:** Andhra cluster on track for similar volume growth, supported by brownfield expansions in **onco and mother and child care**. * **Kerala Strategy:** Volume growth focus in competitive Kerala market, though execution details remain undisclosed. ## C. Bed Occupancy * **Underutilized Capacity:** Telangana and Andhra clusters operate below potential, with current occupancies in the **mid-50% range**, despite **65%–70% feasibility** in Telangana. * **Thane Momentum:** Strong revenue performance in July signals positive ramp, though occupancy remains at **50%–55%** on 100 beds; expansion to 150 beds contingent on reaching **70% utilization**. * **Path to Margins:** Sunshine and Nagpur show clear leverage potential, with **40% margin contribution** from incremental revenue. ## D. New Unit Ramp-Up * **Early-Stage Losses:** Five new hospitals, including Thane and Nashik, are currently dilutive, with **Nashik’s losses expected through Q2** despite cash business traction. * **Ramp Dynamics:** Nashik revenue now at **₹7 Cr/month** on cash-only model; insurance delays continue to constrain full ramp. * **Expansion Timeline:** Small additions (e.g., Ongole) to ramp in **3–4 quarters**, while major expansions (Anantapur, Kondapur, Rajamundry) require **4–5 years** to reach **70%–75% occupancy**. --- # 3. Revenue & Pricing Metrics ## A. Key Figures * **Current ARPOB:** **₹43,000** (company-level) · **₹24,000–25,000** (AP cluster) · **₹69,000** (Telangana) * **Target ARPOB:** **₹50,000–55,000** (post-ramp up of Bangalore & Thane) * **ARPOB Growth Guidance:** **4–5% p.a.** (next 2–3 years) · **5–10%** (initiative-driven upside) ## B. ARPOB Trends * **Divergent Cluster Performance:** Mature clusters (Telangana, Maharashtra, Bangalore) show significantly higher ARPOB than network average, while AP lags due to structural market differences. * **ARPOB Growth Trajectory:** Mid-single-digit annual growth expected, supported by **5% pricing uplift** and gradual mix improvement, though recent bed additions are delaying full stabilization. * **Structural ARPOB Ceiling:** Full convergence between AP and top-tier clusters is unlikely due to inherent differences in patient potential and regional economics. * **Expansion-Driven Upside:** New markets with above-average ARPOB potential will support overall growth, even in absence of formal targets. ## C. Payer & Specialty Mix * **Congo Dominance:** **Congo specialty** drives **60–65%** of total revenue across all regions, with patient mix skewed toward cash-paying initially in new markets like Bangalore. * **High-Value Mix Expansion:** Growing **Congo patient share**—expected to reach **65–70%**—to lift ARPOB, as this segment generates **20–30% higher revenue** than blended average. * **Stable Clinical Mix:** Surgical and medical case composition remains unchanged, with no structural shifts anticipated. --- # 4. Expansion & Capacity ## A. Key Figures * **Network Size:** **25 centers** across 5 states * **Bed Capacity:** **8,000 beds** total network capacity * **Workforce:** **Over 20,000** employees * **New Beds (Bangalore):** **~800 beds** to be commissioned in phases * **New Beds (Srikakulam):** **120-bed hospital** commissioned in Q2 * **Thane Capacity:** **300-bed hospital**, currently operating **100 beds** ## B. Greenfield Progress * **Accelerated Rollout:** New hospitals launched across Thane, Bangalore, Kannur, Kollam, and Andhra Pradesh, with most expected to become operational in the next few quarters. * **Bangalore On Track:** Units in Mahadevpur and Electronic City set to commence operations by end-August, pending final KPME license; near-full licensing already secured. * **Staged Expansion Strategy:** Company prioritizing stabilization of recently launched greenfield sites before advancing new projects, which typically take **3 to 4 years** to complete. * **Oncology Expansion Lagging:** Despite strategic focus, oncology services currently commissioned in only one AP cluster hospital, indicating significant future ramp-up potential. * **Post-Rebuild Constraints:** Secunderabad faces temporary bed shortages due to ongoing reconstruction, limiting volume growth despite high utilization. ## C. Bed Capacity Additions * **Phased Bed Launches:** New facilities like Bangalore and Thane will incrementally add beds—starting with **50–75 per hospital**—scaling with occupancy to optimize performance. * **Capacity Doubling Trend:** Company is almost doubling capacity in key clusters through greenfield additions and brownfield expansions. * **Targeted Oncology Growth:** Gachibowli expansion underway to boost oncology capacity, completing Sunshine’s original growth blueprint. * **Future Footprint Focus:** Expansion beyond FY27 being evaluated in Karnataka, Kerala, Maharashtra, Telangana, and Andhra Pradesh, leveraging proven success in South India. * **Third Hyderabad Facility:** Expected to become operational soon under existing O&M framework, adding to cluster density. --- # 5. Operations & Execution ## A. Key Figures * **O&M Revenue:** **₹4.3 Cr** (Sangli, Q) (no losses) * **Monthly O&M Revenue:** **₹17–18 Cr** per facility (Sangli, Guntur) * **O&M Growth Outlook:** Potential to **double in 3–4 years** ## B. Doctor Recruitment * **Phase 1 Recruitment Largely Complete:** Thane and Sunshine near full staffing; Nashik pending only 2–3 specialties tied to **insurance partner onboarding**. * **Bangalore Onboarding Pending License:** Talent acquisition on track, with 1–3 months required post-approval for transition. * **Specialty Expansion Underway:** Sunshine advancing into oncology and pulmonology via Begumpet expansion, building on strong orthopedics growth. * **Cultural Integration Success:** Positive alignment achieved in Maharashtra and Karnataka, replicating the KIMS model. ## C. Insurance Empanelment * **Custom Rate Negotiations:** Thane, Bangalore, and Nashik undergoing tailored insurance empanelment, not fixed slabs. * **12-Month Empanelment Timeline:** Full process expected to take 9–12 months, with Bangalore initiation in September. * **Reimbursement Support Framework:** Third-party vendors being leveraged to smooth patient reimbursement at new units. ## D. O&M Model Performance * **O&M Model Delivering Results:** Two facilities (Sangli, Guntur) at break-even with **monthly revenue of ₹17–18 Cr**, no capex burden, and full P&L control. * **Revenue Share Structure:** KIMS manages operations entirely for promoters, earning via **revenue share**, with future O&M revenue to be reported separately. * **Technology & Service Diversification:** New capabilities in cancer care (Gachibowli, Begumpet), fertility (Seethammadhara), and pediatric care enhancing clinical scope. * **Strategic Enablers:** AI and digital health platforms deployed to improve outcomes; model supports debt management, scalability, and EBITDA accretion. --- # 6. Risks & Execution Challenges ## A. Licensing & Empanelment Delays * **Licensing Holds Up Openings:** Unit launches delayed by **1–2 months** due to pending government approvals. * **Insurance Empanelment Critical for Ramp-Up:** Slow start in Nashik and expected delays in Bangalore stem from time-intensive insurer tie-ups, a common hurdle for new hospitals. * **Path to Revenue Growth:** Completion of insurance and CGHS empanelment—covering **60% of typical hospital volumes**—expected within **3–6 months**, with full empanelment resolving patient attrition. * **Complex, Prolonged Process:** Bilateral tariff negotiations and micro-market dynamics make empanelment cumbersome; multicity hospitals may see faster track, but **9–12 months remains a prudent timeline**. ## B. Regional Ramp-Up & Operational Pressures * **AP Cluster Margin Pressure:** Preoperative costs from Srikakulam launch and QNRI hospital renovations, including incremental doctor hiring, weighed on margins. * **Persistent Patient Leakage:** Cumbersome reimbursement processes deter patients despite clinical readiness, highlighting demand for seamless cashless access. * **Competitive Dynamics:** Telangana faces intense competition, yet the company achieved volume and revenue growth; newer clusters report no competitive pressure. * **Doctor Retention Strength:** No doctor attrition in 2–3 years despite market poaching, as most competitive capacity is already operational. * **Challenges in Maharashtra:** Doctor onboarding slower than in South India due to **cultural differences in medical practice models**. ## C. Growth Constraints & Capital Discipline * **Near-Term O&M Capacity Full:** No new O&M contracts expected in next 3 quarters due to bandwidth constraints from ongoing ramp-ups in **Nashik, Thane, and upcoming Bangalore unit**. * **Capital Deployment Cautious:** Capex being allocated meticulously to ensure sustainable, controlled expansion. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Guidance:** **INR5–10 Cr** expected impact from cluster shifts * **O&M Revenue Target:** **INR9 Cr** (up to 9%) from O&M stream · **INR100 Cr/month** total top-line target * **EBITDA Margin Outlook:** **22%–25%** for current fiscal * **New Hospital Losses:** **INR20–25 Cr** expected in Q2 · **INR20–30 Cr** estimated for FY2027 * **Bangalore Commissioning Drag:** **INR10–15 Cr** financial impact in September * **ROCE Target:** **20%–25%** for ramped-up new facilities ## B. Revenue Projections * **Regional Revenue Divergence:** Anticipated improvement in Maharashtra and Kerala clusters partially offset by Telangana drag, reflecting uneven regional ramp-up dynamics. * **Growth Sustainability:** Target to maintain decade-long CAGR supported by O&M models and strategic focus on high-return Andhra Pradesh units. * **O&M Scalability:** O&M stream positioned as a key growth lever, contributing meaningfully to monthly revenue targets. ## C. Margin Targets * **Margin Resilience:** Full-year EBITDA margin guidance remains robust at 22–25%, despite near-term dilution from new unit ramp-up. ## D. EBITDA Timeline * **Near-Term EBITDA Pressure:** New hospital losses to rise QoQ, with Q2 losses concentrated in Nashik, Thane, and newly commissioned Bangalore facilities. * **Path to Breakeven:** Bangalore hospitals expected to reach EBITDA breakeven within **12 months** of full operations, contingent on achieving **30–40% occupancy**. * **Loss Containment:** No new greenfield projects beyond Q2 FY2027, implying EBITDA losses from new assets should taper by FY2028. * **Longer-Term Ramp-Up:** Full commissioning and 70% occupancy at Thane’s 300 beds expected over **3–4 years**, indicating prolonged investment phase. * **Occupancy-Driven Margins:** Telangana cluster margins seen trending upward at **65–70% occupancy**, highlighting leverage potential post-ramp.